RxDoctor Payments Data

Roland Friedman, MD

Urology · Winston Salem, NCNPI 1790747004

Payments from drug & device makers

$3,458in general payments, 2019–2025

Across 39 payments — averaging $88.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Urogen Pharma, Inc.$593
  • Neotract Inc.$207
  • SWAN Valley Medical Incorporated$196
  • Boston Scientific$133
  • Myovant Sciences Inc.$118
  • plus $740 from 12 others

What the payments were for

  • Consulting fees$1003%
  • Food & beverage$3,26995%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,458 in reported general payments places this provider in the 55th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$206,508
Medicare patients
890
Services billed
2,836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron273$213,018
GemtesaVibegron52$35,559
Tamsulosin Hcl1,763$27,519
Methenamine Hippurate195$11,732
Finasteride768$10,525
Solifenacin Succinate206$8,933
Trospium Chloride174$8,843
Silodosin118$8,734
Dutasteride267$7,838
Trimethoprim195$7,699
Alfuzosin Hcl ErAlfuzosin Hcl330$6,306
Trospium Chloride ErTrospium Chloride28$5,776
Testosterone34$4,746
Fesoterodine Fumarate ErFesoterodine Fumarate39$2,719
Testosterone Cypionate110$2,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$88$213,018273 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 434 urology providers in North Carolina.

Other urology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →